Ono strikes two deals as it shores up mid-stage pipeline
This article was originally published in Scrip
Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Servier's If channel agonist ivabradine and KAI Pharmaceuticals' secondary hyperparathyroidism therapy KAI-4169.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.